The Role of Chemotherapy in Recurrent Malignant Gliomas: An Overview
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 14 (6) , 551-559
- https://doi.org/10.3109/07357909609076900
Abstract
First-line treatment of malignant gliomas invariably includes surgery when feasible, and often adjuvant radiotherapy with or without chemotherapy; at progression or recurrence, the only remaining possibility is chemotherapy. While the role of first-line treatment has been established by many randomized studies, second-line treatment is not as well defined. To analyze the difficulties encountered with cytotoxic drugs in relation to both the blood-brain barrier and drug resistance, we examined the results obtained by single-agent chemotherapy, drug combinations, and biological response modifiers. Our findings confirmed that the nitrosoureas are the most active substances at the time of recurrence; these agents give an approximately 30% global response rate, with about 20 weeks' survival. Although no comparative randomized studies regarding single- versus multiple-agent chemotherapy are available, the latter approach, including nitrosourea, can obtain an up to 40% rate of response, with survival ranging from 30 to 50 weeks. The role of interferons has been very controversial; individually, alpha- and beta-interferons seem to give a 20% response rate, with 20 weeks' survival. To date, they have never been used in combination with cytotoxic drugs, but they may prove synergistic without increasing toxicity. Studies addressing the quality of life of these patients are not available, and it is clear that we need more basic research in this field.Keywords
This publication has 63 references indexed in Scilit:
- Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignanciesJournal of Neuro-Oncology, 1993
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal Of Cancer, 1993
- Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: A phase II studyJournal of Neuro-Oncology, 1993
- Phase II study of tauromustine in malignant gliomaEuropean Journal Of Cancer, 1992
- Phase II study of fotemustine in recurrent supratentorial malignant gliomasEuropean Journal of Cancer and Clinical Oncology, 1991
- Clinical effect of interferon in malignant brain tumoursNeurosurgical Review, 1984
- Vm-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: Preliminary reportSurgical Neurology, 1981
- Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after SurgeryNew England Journal of Medicine, 1980
- THE DEVELOPMENT AND ULTRASTRUCTURE OF THE MICROVASCULATURE IN MALIGNANT GLIOMASNeuropathology and Applied Neurobiology, 1977
- The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrierJournal of Pharmacokinetics and Biopharmaceutics, 1976